Cited by 44Ovarian function and disordersAdipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients

Open access
Victor, Victor M., Rovira-Llopis, Susana, Bañuls, Celia, Diaz-Morales, Noelia, Lopez-Domenech, Sandra, Escribano-López, Irene, Rios-Navarro, Cesar, Alvarez, Angeles +3 more·2015·Atherosclerosis

Abstract

Objective We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects.Methods The study population consisted of 40 reproductive-age women with PCOS, who underwent treatment with metformin during a 12-week period, and their corresponding matched controls (n = 44). We evaluated endocrinological parameters, adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)) in serum. In addition, interactions between human umbilical vein endothelial cells and polymorphonuclear (PMN) cells were assessed by flow chamber microscopy. In addition, a group of type 2 diabetes patients who underwent treatment with metformin during a 12-week period was incorporated into the study.Results Metformin produced beneficial effects on PCOS patients by decreasing polymorphonuclear (PMN) rolling flux and adhesion. It also decreased levels of ICAM-1, E-selectin, IL-6 and ΤΝFα. In addition, metformin induced an improvement of endocrine and anthropometric parameters in PCOS subjects by reducing glucose, follicle-stimulating hormone (FSH) and androstendione, and by increasing dehydroepiandrosterone-sulfate (DHEA-S). Metformin also had beneficial effects in type 2 diabetic subjects by reducing body weight, waist circumference and PMN adhesion, and by increasing PMN rolling velocity.Conclusion Our results highlight the modulating effect of metformin on leukocyte/endothelium interactions. These findings may explain the potential beneficial effect of metformin in reducing the risk of vascular events in PCOS patients and in insulin resistance conditions.

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2015.07.017

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin has additional benefit for conditions like polycystic ovary syndrome, atherosclerosis, cancer, COVID-19, and obesity.

    “Aside from its anti-hyperglycemic effects, metformin has an additional benefit for conditions like polycystic ovary syndrome, atherosclerosis, cancer, coronavirus disease 2019 (COVID-19), and obesity (7–14).”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Victor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Lopez-Domenech, S., Escribano-López, I., Rios-Navarro, C., Alvarez, A., Gomez, M., Rocha, M., & Hernandez-Mijares, A.
Affiliations
Universitat de València (ES)
Corresponding author
Rocha, Milagros
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2015-09
Volume
242
Issue
1
Pages
167-173
ISSN
0021-9150 (ISSN-L)
OpenAlex
W1597382019
Cited by
44
References
46
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 5
FWCI
5.70
Type
journal article
Language
en
Open access
Locations
  • Atherosclerosis (publishedVersion)
  • PubMed (publishedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
  • Zenodo (CERN European Organization for Nuclear Research)
Funders
  • FISABIO (PI12/1984, PI13/1025, PI13/0073, UGP14-093, UGP14-095)
  • CIBERehd (CB06/04/0071)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
metformin, polycystic ovary syndrome, leukocyte-endothelium interaction, endothelial function, adhesion molecules, inflammatory cytokines, interleukin-6, TNF-α, type 2 diabetes, insulin resistance, VCAM-1, E-selectin, DHEA sulfate, androstenedione, follicle-stimulating hormone
MeSH terms
Adolescent, Adult, Cell Adhesion, Cells, Cultured, Diabetes Mellitus, Type 2, Female, Humans, Leukocytes, Metformin, Polycystic Ovary Syndrome, Spain, Time Factors, Biomarkers, Cell Adhesion Molecules, Cytokines, Treatment Outcome, Inflammation Mediators, Coculture Techniques, Leukocyte Rolling, Endothelial Cells, Young Adult, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review